- Omega Therapeutic Inc OMG presented new preclinical data on its lead product candidate, OTX-2002, in several models of hepatocellular carcinoma.
- In non-human primates, treatment with OTX-2002 resulted in sustained reduction of MYC mRNA levels in the liver, consistent with previous in vitro and in vivo studies.
- OTX-2002 treatment decreased c-Myc mRNA, protein levels, and cell viability in several HCC cell lines while sparing normal cells.
- Related: Omega Therapeutics submits IND for liver cancer candidate.
- OTX-2002 significantly reduced tumor growth in HCC xenograft models.
- OTX-2002 treatment is associated with decreased expression of immune checkpoint factor PD-L1 in HCC cells, suggesting a potential role for combination therapy with immune checkpoint inhibitors.
- The combination of OTX-2002 with existing standard of care therapies for HCC resulted in further reduction of cell viability and tumor burden in in vitro and in vivo HCC models.
- Price Action: OMGA shares are down 1.41% at $4.20 in Thursday’s last check trading session.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.